Elevian is a groundbreaking brand that specializes in the development of innovative medicines targeting recovery and regeneration. Their lead program focuses on a recombinant protein called rGDF11, designed to treat strokes in the critical days following the event. With stroke being a leading cause of disability and death globally, Elevian aims to fill the gap in the market, as there are currently no viable treatments available for stroke recovery.

rGDF11 has shown promising results in animal models, promoting neovascularization and neurogenesis, reducing inflammation, and facilitating motor function recovery. Moreover, Elevian's research suggests that rGDF11 has the potential to address various aging-associated diseases, such as cardiovascular, neurological, metabolic, pulmonary, renal, inflammatory, and skeletal muscle dysfunction. Comprised of a team of experienced leaders, Elevian is committed to revolutionizing the field of regenerative medicine.

Their core values of kindness, diligence, openness, community, responsibility, and fun guide their endeavors. Don't miss the opportunity to learn more about their groundbreaking science and the transformative potential of their innovative approach to aging-related diseases